Table 2.
Fasting serum and urine biochemistries on placebo and calcium carbonate a
| p-value | |||||
|---|---|---|---|---|---|
| Placebo | Calcium | Placebo v. Calcium | Reference Range | (source) | |
| sCa, mg/dL | 9.5 0.1 (9.0, 9.9) | 9.7 0.1 (8.8,10.2) | 0.15 | 8.8–10.2 | KDOQI |
| sPi, mg/dL | 3.8 0.1 (3.3, 4.2) | 4.0 0.1 (3.7, 5.2) | 0.29 | 2.3 – 4.5 | KDOQI |
| s25OHD, ng/mL | 26.7 0.4 (20.1, 39.7) | 25.1 0.4 (18.5, 37.6) | 0.03 | 15 – 80 | Merck Manual |
| s1,25OH2D, pg/mL | 33.1 2.3 (15.7, 57.9) | 30.6 2.3 (15.6, 62.9) | 0.49 | 25 – 65 | Merck Manual |
| sPTH, pg/mL | 63.1 3.0 (38.2, 111.5) | 58.9 3.0 (26.7, 113.1) | 0.37 | 13 – 54 | (Diasorin Assay) |
| sFGF23, pg/mL | 75.6 14.5 (52.4, 142.5) | 89.9 14.5 (38.7, 286.1) | 0.51 | 8.2 – 54.3 | (Kianos Assay) |
| sOC, ng/mL | 20.8 1.2 (14.0, 41.3) | 20.1 1.2 (14.7, 34.5) | 0.71 | 3.7 – 10.0 | (MicroVue Assay) |
| sBAP, U/L | 31.9 1.0 (21.2, 47.4) | 32.4 1.0 (19.7, 51.7) | 0.73 | Men: 15.0 – 41.3 Women: 14.2 – 42.7 |
(MicroVue Assay) (post-menopausal) |
| uNTX/Cr, nM/mM | 38.8 4.1 (19.8, 66.1) | 34.9 4.1 (12.1, 96.4) | 0.53 | Men: 3 – 63 Women: 5 – 65 |
(Osteomark Assay) (pre-menopausal) |
| uCa/Cr | 0.03 0.01 (0.003, 0.12) | 0.03 0.01 (0.002, 0.14) | 0.82 | ||
| uPi/Cr | 0.4 0.04 (0.2, 0.7) | 0.4 0.04 (0.05, 0.52) | 0.24 | ||
| TmP, mg/100mL GF | 2.8 0.1 (2.5, 3.3) | 3.1 0.1 (2.7, 3.8) | 0.11 | ||
| CPi/CCr | 0.23 0.01 (0.11, 0.30) | 0.19 0.01 (0.02, 0.24) | 0.10 | ||
| TmCa, mg/100mL GF | 5.2 0.04 (4.7, 5.5) | 5.3 0.04 (4.5, 5.7) | 0.22 | ||
| CCa/CCr | 0.01 0.003 (0.001, 0.05) | 0.01 0.003 (0.001, 0.06) | 0.94 | ||
a
Values are least squares means and pooled SEM (Min, Max), n = 8. For each patient, the values during placebo and calcium carbonate are the average of three fasting measurements.